Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOXYCYCLINE vs ACHROMYCIN V
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.
Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-t RNA binding to m RNA-ribosome complex.
Empiric treatment of acute bacterial exacerbations of COPD,Community-acquired pneumonia,Prostatitis caused by Chlamydia trachomatis,Treatment of Lyme disease,Treatment of Rocky Mountain spotted fever,Acne vulgaris (off-label),Malaria prophylaxis (off-label)
Infections caused by susceptible strains of bacteria including rickettsiae, Mycoplasma pneumoniae, Chlamydia trachomatis, and spirochetes,Acne vulgaris,Adjunctive therapy in severe acne,Off-label: Chronic prostatitis, sclerosing keratitis, rosacea
100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.
250-500 mg orally every 6 hours
Terminal elimination half-life is 18–24 hours in patients with normal renal function; prolonged to 20–30 hours in renal impairment; allows once or twice daily dosing.
Terminal elimination half-life is 6-12 hours in patients with normal renal function; prolonged in renal impairment (up to 48-72 hours in anuria).
Doxycycline is partially metabolized in the liver via unspecified pathways; it is not significantly metabolized by CYP450 enzymes. Approximately 40% is excreted renally as active drug.
Not extensively metabolized; primarily excreted unchanged in urine via glomerular filtration; small amount metabolized in liver.
Renal (40%) and fecal/biliary (60%); undergoes enterohepatic circulation; active drug and metabolites excreted in urine and feces.
Renal (60% unchanged in urine via glomerular filtration), biliary/fecal (40% as active drug and metabolites, with a portion undergoing enterohepatic recirculation).
80–93% bound to plasma proteins, primarily albumin.
50-65% bound to serum albumin; primarily binds to alpha-1-acid glycoprotein.
0.75–1.3 L/kg, indicating extensive tissue penetration; high concentrations in lung, liver, bone, and prostate.
1.5-2.0 L/kg (large volume indicates extensive tissue distribution, concentrating in bile, liver, kidneys, and bone; minimal CNS penetration despite lipophilicity).
Oral: 90–100% (well absorbed); IV: 100%; topical: minimal systemic absorption (<10%).
Oral: 60-80% (reduced by food, particularly dairy products, due to chelation with divalent cations). Intravenous: 100%.
For Cr Cl < 50 m L/min: no dosage adjustment required for most indications; for severe infections or prolonged use, consider monitoring renal function. In patients with Cr Cl < 10 m L/min, reduce dose or avoid if possible due to potential anti-anabolic effect.
GFR 50-80 m L/min: no adjustment; GFR 10-50 m L/min: 250-500 mg every 12-24 hours; GFR <10 m L/min: 250-500 mg every 24 hours
Child-Pugh A: no adjustment. Child-Pugh B: use with caution; no specific dose reduction recommended. Child-Pugh C: avoid use due to lack of safety data.
No dosage adjustment required; use with caution in severe hepatic impairment due to potential hepatotoxicity
For children >8 years and weighing ≤45 kg: 2.2 mg/kg every 12 hours on day 1, then 2.2 mg/kg once daily or 1.1 mg/kg every 12 hours. For children >45 kg: same as adult. For children <8 years: contraindicated due to risk of permanent tooth discoloration and enamel hypoplasia.
Children >8 years: 25-50 mg/kg/day orally divided every 6 hours
No specific dose adjustment required; use standard adult dosing. Monitor renal function and consider potential increased risk of photosensitivity reactions. Avoid in elderly with impaired renal function if alternative agents available.
Consider age-related renal impairment; adjust dose based on GFR; avoid if possible due to increased risk of photosensitivity and gastrointestinal effects
There is no FDA black box warning for doxycycline.
Use during tooth development (last half of pregnancy, infancy, childhood to age 8 years) may cause permanent discoloration of teeth (yellow-gray-brown).
Photosensitivity: avoid prolonged sun exposure,Esophageal injury: take with adequate fluids,Hepatotoxicity: caution in hepatic impairment,Intracranial hypertension: risk of pseudotumor cerebri,Delay in bone growth and tooth discoloration in children <8 years,C. difficile-associated diarrhea,Superinfection with resistant organisms
Photosensitivity manifested by exaggerated sunburn reaction,Renal impairment may lead to drug accumulation and potential hepatotoxicity,Superinfection with resistant organisms including fungi,Bone growth retardation in premature infants,Pseudotumor cerebri (benign intracranial hypertension) in adults
Hypersensitivity to tetracyclines,Children <8 years of age (except for anthrax or severe infections),Pregnancy (especially second and third trimesters)
Hypersensitivity to tetracyclines,Pregnancy,Children under 8 years of age,Severe renal or hepatic impairment
Dairy products (milk, cheese, yogurt), calcium-fortified foods, antacids containing aluminum, calcium, magnesium, and iron supplements can chelate doxycycline, reducing absorption. Separate intake by at least 2 hours. Alcohol is not known to interact significantly. Avoid taking with high-iron foods like spinach or red meat within 2 hours.
Avoid dairy products (milk, cheese, yogurt) and calcium-fortified foods within 2-4 hours of dosing. Also avoid concurrent intake of iron-rich foods or supplements, zinc, magnesium, and antacids. High-fat meals may reduce absorption; take on an empty stomach.
Category D. Avoid in pregnancy. Risk of fetal harm including permanent tooth discoloration and impaired bone growth when used in second and third trimesters. First trimester use associated with neural tube defects, cardiovascular malformations, and spontaneous abortion. Hepatic necrosis in pregnant women reported.
Tetracyclines, including ACHROMYCIN V (tetracycline hydrochloride), are classified as FDA Pregnancy Category D. Use during the second and third trimesters may cause permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus. Reversible inhibition of bone growth has been reported. First-trimester exposure is associated with a small risk of neural tube defects and other malformations in some studies. Avoid use during pregnancy unless for serious infections (e.g., anthrax, brucellosis) when alternative antibiotics are contraindicated.
Doxycycline is excreted into breast milk in low concentrations (M/P ratio ~0.2-0.6). Theoretical risk of dental staining and bone growth suppression in nursing infants. American Academy of Pediatrics considers compatible with breastfeeding due to low absorption, but alternative antibiotics preferred.
Tetracycline is excreted into human milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.6–0.8. Theoretical risks include dental staining and bone growth inhibition in the nursing infant. Short-term use at recommended doses is generally considered compatible with breastfeeding by the American Academy of Pediatrics, but prolonged or repeated courses should be avoided. Monitor infant for potential gastrointestinal disturbances or rash.
Increased renal clearance and volume of distribution during pregnancy may reduce serum concentrations, but no dose adjustment recommended due to teratogenicity. Use only if absolutely necessary with caution.
Pregnancy reduces tetracycline serum concentrations due to increased volume of distribution and enhanced hepatic clearance. However, dose adjustments are not routinely recommended because the drug is generally avoided in pregnancy. If use is unavoidable (e.g., anthrax), standard adult doses (e.g., 250-500 mg every 6 hours) may be insufficient; consider monitoring serum levels if available and adjusting based on clinical response. Avoid in the second and third trimesters if possible.
Administer with a full glass of water to reduce esophageal irritation; avoid lying down for 30 minutes after dosing. Tetracyclines bind calcium, so avoid dairy, antacids, and iron within 2 hours of dosing. Use sun protection due to photosensitivity. In children under 8, pregnant, or breastfeeding, avoid due to tooth discoloration and bone growth inhibition. Monitor for superinfection, especially Clostridioides difficile. Dose adjustment not needed in renal impairment but caution in hepatic impairment.
Tetracycline chelates with divalent and trivalent cations; avoid concurrent administration with dairy, antacids, iron, or calcium supplements. Photosensitivity risk: advise sun avoidance and use of sunscreen. Monitor renal function in elderly; adjust dose in severe renal impairment. Not for use in pregnancy or children under 8 years due to tooth discoloration and bone growth inhibition. Administer on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption.
Take exactly as prescribed; finish the full course even if you feel better.,Take with a full glass of water and remain upright for 30 minutes after.,Avoid dairy products, antacids, calcium supplements, iron, and magnesium within 2 hours of taking doxycycline.,Use sunscreen and protective clothing; avoid prolonged sun exposure as it can cause severe sunburn.,Do not take if pregnant, breastfeeding, or if you have a child under 8 years old.,Report any signs of severe diarrhea, skin rash, or difficulty swallowing to your doctor.,Store at room temperature away from moisture and heat; do not use outdated medication.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Avoid dairy products, antacids, iron supplements, and calcium supplements within 2-4 hours of taking this drug.,Protect your skin from sun exposure; use sunscreen and wear protective clothing as this medicine can cause severe sunburn.,Do not take this drug if you are pregnant or breastfeeding; it can harm the baby's teeth and bones.,Complete the full course of treatment even if you feel better; do not skip doses.,Report any signs of allergic reaction, severe headache, blurred vision, or persistent diarrhea to your doctor immediately.,Store at room temperature away from moisture and light.
"Hydrocortisone, a corticosteroid, may inhibit the hepatic metabolism of doxycycline, a tetracycline antibiotic, leading to increased doxycycline plasma concentrations. This elevation can potentiate doxycycline's adverse effects, such as gastrointestinal disturbance, photosensitivity, and hepatotoxicity. Clinically, this interaction may reduce the therapeutic window of doxycycline, requiring dose adjustment or alternative therapy selection."
"Ketobemidone, an opioid analgesic, may inhibit the cytochrome P450 enzyme CYP3A4, which is involved in the metabolism of doxycycline. This can lead to reduced clearance and increased plasma concentrations of doxycycline, potentially enhancing its antibiotic effects or increasing the risk of adverse effects such as photosensitivity, gastrointestinal disturbances, or hepatic toxicity."
"Clobazam, a benzodiazepine and CYP3A4 inducer, may increase the metabolism of doxycycline, a tetracycline antibiotic, reducing its plasma concentration and potentially compromising its antibacterial efficacy. This interaction could lead to subtherapeutic doxycycline levels, increasing the risk of treatment failure or microbial resistance. Conversely, doxycycline may inhibit CYP3A4, potentially elevating clobazam concentrations, though the clinical significance of this effect is less clear."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOXYCYCLINE vs ACHROMYCIN V, answered by our medical review team.
DOXYCYCLINE is a Tetracycline Antibiotic that works by Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.. ACHROMYCIN V is a Tetracycline Antibiotic that works by Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-t RNA binding to m RNA-ribosome complex.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOXYCYCLINE and ACHROMYCIN V depend on the specific clinical indication. These are both Tetracycline Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOXYCYCLINE is: 100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.. The standard adult dose of ACHROMYCIN V is: 250-500 mg orally every 6 hours. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOXYCYCLINE and ACHROMYCIN V in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOXYCYCLINE is classified as Category D/X. Category D. Avoid in pregnancy. Risk of fetal harm including permanent tooth discoloration and impaired bone growth when used in second and third trimesters. First trimester use as. ACHROMYCIN V is classified as Category C. Tetracyclines, including ACHROMYCIN V (tetracycline hydrochloride), are classified as FDA Pregnancy Category D. Use during the second and third trimesters may cause permanent tooth. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.